{"id":"W4220721699","doi":"10.1002/cam4.4635","title":"A <scp>WIN</scp> Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non‐small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; Waterloo Institute for Nanotechnology, University of Waterloo; University of California, San Diego; Fondation ARC pour la Recherche sur le Cancer; Pfizer","keywords":"Axitinib; Medicine; Avelumab; Palbociclib; Internal medicine; Oncology; Neutropenia; Lung cancer; Pembrolizumab; Cancer; Adverse effect; Gastroenterology; Immunotherapy; Chemotherapy; Breast cancer; Sunitinib; Metastatic breast cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002507428,0.0007487058,0.0007735153,0.0003656918,0.0004772532,0.0008660998,0.0006449408,0.0006767507,0.003205628],"category_scores_gemma":[0.0004885915,0.0002955082,0.0007921258,0.0003936949,0.0007630069,0.0004851704,0.0004915604,0.001807287,0.0005244731],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001354943,"about_ca_system_score_gemma":0.002991906,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002844151,"about_ca_topic_score_gemma":0.00686845,"domain_scores_codex":[0.9994543,0.0002622617,0.00002874653,0.00008108877,0.00007009166,0.0001035984],"domain_scores_gemma":[0.9991739,0.00006457429,0.00009998629,0.0000462979,0.00006062694,0.0005545883],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4813716,0.1111168,0.07181703,0.0009304868,0.002647114,0.0009141967,0.0004364753,0.005073972,0.1142699,0.001079067,0.02242854,0.1879148],"study_design_scores_gemma":[0.4920955,0.4092279,0.07016591,0.00005783952,0.0009159819,0.001003912,0.000131797,0.002899066,0.0115014,0.0003584701,0.01159874,0.00004351009],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930546,0.001018358,0.0002926152,0.000647996,0.00005179036,0.001772717,0.0008406859,0.00005276824,0.002268566],"genre_scores_gemma":[0.9904999,0.0007455847,0.001400165,0.0007676684,0.00009059472,0.001371774,0.002552064,0.00002551357,0.00254664],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003205628,"threshold_uncertainty_score":0.01326072,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04458647732105899,"score_gpt":0.344888726281933,"score_spread":0.300302248960874,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}